Intrinsiqq
Fulcrum Therapeutics Inc. logo

Fulcrum Therapeutics Inc. Quality Score

FULC

Compare
Quality10

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-3.6x

Negative earnings, no valuation support

Cash Flow Multiple
0/100
-4.3x

Negative FCF, no valuation support

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
0/100
69.6%

Heavy dilution above 5%

Capital Structure
100/100
-$110M

Net cash position, no leverage concern

2022
$35.0M
$13.0M
2023
$26.0M
$11.0M
2024
$58.0M
$9.00M
2025
$198M
$6.00M
TTM
$116M
$7.00M
CashDebt
Return on Capital
0/100
-21.1%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Fulcrum Therapeutics (FULC) quality: score, margins and returns

Fulcrum Therapeutics (FULC) scores 10/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 4 metrics each scored 0 to 100 and -21.1% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Fulcrum Therapeutics (FULC) a high-quality business?+

Fulcrum Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -21.1% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Fulcrum Therapeutics's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from FULC's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Fulcrum Therapeutics scores well and where it falls behind.

What is Fulcrum Therapeutics's return on invested capital (ROIC)?+

Fulcrum Therapeutics earns about -21.1% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to FULC's margins and growth on this scorecard to judge durability.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 8 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 13 Nov 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Pharmaceutical Preparations · Pick stocks to compare with FULC

CompareIntrinsic value
KURAKura Oncology Inc.
$6.91-5.99%10
GOSSGossamer Bio Inc.
$10.72-4.54%10
BCYCBicycle Therapeutics PLC
$2.90-4.92%40
LABStandard Biotools Inc.
$0.63+3.28%35
ADCTADC Therapeutics S.A.
$1.29-0.77%10
OMEROmeros Corporation
$13.21-5.71%28
AMLXAmylyx Pharmaceuticals, Inc.
$26.02-0.69%10
RMTIRockwell Medical, Inc.
$5.82-7.03%34

Held by ETFs

FULC is in 15 US ETFs. The largest of them, with FULC's weight in each:

Spot a number that looks wrong? Check it in FULC's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing FULC

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.